Media headlines about Merus (NASDAQ:MRUS) have trended somewhat positive this week, Accern Sentiment Analysis reports. The research firm scores the sentiment of press coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Merus earned a media sentiment score of 0.08 on Accern’s scale. Accern also assigned media coverage about the biotechnology company an impact score of 48.2339768664876 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.

Shares of NASDAQ:MRUS traded down $0.05 during midday trading on Friday, hitting $20.29. The company had a trading volume of 1,700 shares, compared to its average volume of 50,191. The firm has a market capitalization of $449.33 million, a price-to-earnings ratio of -4.74 and a beta of -0.14. Merus has a 12-month low of $13.67 and a 12-month high of $26.74.

Merus (NASDAQ:MRUS) last issued its earnings results on Thursday, July 26th. The biotechnology company reported ($0.48) earnings per share for the quarter, topping the consensus estimate of ($0.81) by $0.33. The company had revenue of $11.84 million during the quarter, compared to the consensus estimate of $3.47 million. Merus had a negative net margin of 178.79% and a negative return on equity of 67.34%. research analysts anticipate that Merus will post -2.6 earnings per share for the current year.

Several equities research analysts have recently commented on the company. BidaskClub upgraded Merus from a “buy” rating to a “strong-buy” rating in a research note on Saturday, June 30th. ValuEngine lowered Merus from a “hold” rating to a “sell” rating in a research note on Wednesday, May 30th. Finally, Zacks Investment Research upgraded Merus from a “hold” rating to a “buy” rating and set a $20.00 price objective for the company in a research note on Friday, May 4th. Three analysts have rated the stock with a hold rating and three have issued a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $29.00.

Merus Company Profile

Merus N.V., a clinical-stage immuno-oncology company, engages in developing bispecific antibody therapeutics. Its bispecific antibody candidate pipeline includes MCLA-128, which is in a Phase II clinical trial for the treatment of patients with metastatic breast cancer; and Phase I/II study for treating gastric, ovarian, endometrial, and non-small cell lung cancers.

Recommended Story: Short Selling – Explanation For Shorting Stocks

Insider Buying and Selling by Quarter for Merus (NASDAQ:MRUS)

Receive News & Ratings for Merus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merus and related companies with's FREE daily email newsletter.